A note before you read further: this article is a discussion of how to think about deal structure and M&A, not advice on what to do. Every deal and every doctor's situation is different. Talk to your own attorney and CPA before making any decisions about a practice sale.

Let's be straight about what dental practice acquisitions look like heading into 2027: it's selective, it's slower than you probably hoped, and it's probably going to stay that way for a while.

Interest rates haven't come down. Financing remains expensive. Deal flow is nowhere near 2021 levels. And the gap between what sellers think their practice is worth and what buyers are willing to pay is real, and it's not closing fast.

But this selective environment isn't all bad. It's actually revealing which DSO platforms are built to last, and which ones are built on hype and acquisition momentum. The groups that are winning in 2027 are the ones that invested in the fundamentals years ago: sustainable growth, operational discipline, smart technology choices, and genuine profitability.

If you're thinking about M&A in 2027, here's what you need to know.

Where dental practice acquisitions stand heading into 2027

Dental deal activity in 2026

Deal flow through 2026 came in slower than most expected because interest rates remained high and financing stayed expensive.

The deals that did close had some things in common:

  • Both buyer and seller were realistic
  • Valuations aligned
  • Operations were clean
  • There was genuine cultural and strategic fit
  • Integration plans were thoughtful and realistic

Transactions that dragged on or didn't close? They typically had different characteristics: valuations that couldn't bridge the gap, complex operational structures that would require massive post-close work, or a patchwork of different systems and processes that would take years to untangle.

The reality is 2026 separated the serious players from the optimists. Groups with solid fundamentals found buyers. Groups banking on things improving? They're more likely to still be waiting.

What DSOs and sponsors expect for 2027

The experts we’ve spoken to believe 2027 will look a lot like 2026. That means buyers are being selective, and sellers need to bring their A-game.

If acquisition is on your roadmap for 2027, expect to compete on fundamentals like:

  • Clean, honest financials that pass scrutiny
  • Proven organic growth within your existing practices
  • Providers who are engaged and stable
  • Operations that actually work the way you say they work

The groups that will successfully execute M&A in 2027 are those that have built real, sustainable value, not just those that added the most practices.

What is driving DSO acquisition momentum

Dental private equity, sponsor capital, and recapitalization expectations

Private equity sponsors haven't left the dental sector. They're just evaluating platforms differently than they did five years ago, and the days of practice count being basically the only metric that mattered are long over.

Here's what we're seeing sponsors care about now:

Same-source revenue growth. Are you growing revenue in existing locations or is all your growth just adding more practices? Organic growth is often more valuable to sponsors because it's sustainable.

How your operations actually work. Do you have centralized revenue cycle management? Are back-office decisions made at the group level? Or does each practice run like its own little business? Centralization scales. Decentralization creates chaos.

Your technology strategy. Do you have one unified PMS, or are you running multiple different systems? Groups with unified platforms are dramatically more efficient, and sponsors know it.

Provider alignment. Does your compensation model make sense, and do dentists want to stay, or are they looking for the exit? Misaligned provider economics can destroy value quickly.

Measurable outcomes. What's your treatment acceptance rate? Your patient retention rate? Case completion rate? Sponsors want to see real numbers that suggest operational maturity.

Your debt. How much are you carrying, and what did you pay for it? If you took on expensive debt in the past few years, you may have limited capital flexibility for the next few years.

The bottom line: sponsors want platforms that are actually well-run.

The supply of practices coming to market

The supply of practices available for acquisition in 2027 will depend on individual platform strategies. Some groups are acquisition focused. Some pursue de novo development almost exclusively. Many operate hybrid approaches.

Acquisition sourcing for 2027 is likely to include:

  • Independent practices with aging owner-operators seeking transitions
  • Practices being rationalized from larger platforms
  • New dental graduates or younger providers building their first practices
  • Practices in markets attractive to strategic buyers or platforms with geographic expansion objectives

De novo sourcing requires different infrastructure entirely: strong recruiting pipelines, startup capital, management bandwidth, and realistic expectations about time-to-profitability (typically 3-5 years).

The key question: Do you have the infrastructure to execute your chosen growth model? If not, be honest about it. Pursuing a strategy you're not built for is a path to frustration.

How valuations and deal terms could change

Valuation ranges and the outlook for practice pricing

Let's talk numbers, because this matters if you're thinking about selling.

2021 was peak market. People were bidding aggressively, debt was cheap, and everyone thought growth would be infinite.

Today, many quality practices are trading at lower EBITDAs, and less profitable or more complex practices might be even lower. That's a significant compression, and it reflects the real economics of today's financing costs.

What impacts valuation in 2027:

  • How profitable are your practices?
  • Are you growing revenue or just adding practices?
  • How clean is your operational data?
  • What does your debt structure look like?
  • Do providers want to stay post-close?

If you're waiting for 2021 multiples to come back, don't expect that to happen in 2027. Be realistic about what the market is actually paying.

What could slow dental M&A in 2027

Financing conditions and delayed transactions

If the Fed raises rates further, deal activity will likely slow even more. If rates stay where they are, we expect to see deal activity at a measured pace. If rates come down (our experts are not predicting that), then we might see more activity.

Many deals are taking longer to close (if they close at all), and deal flow will likely remain constrained throughout 2027.

State scrutiny and corporate ownership restrictions

Different states have different rules about how DSOs can operate. If you're expanding into new states, factor regulatory complexity into your evaluation. It can impact valuation and timeline.

This regulatory uncertainty won't dramatically slow the market, but it may create friction and reduce valuations in restricted states, and you should factor this into your planning.

Why seller priorities matter in DSO acquisitions

Clinical autonomy and post-sale working arrangements

Buyer and seller priorities can trip up a lot of deals.

Sellers often prioritize:

  • Staying involved clinically post-close
  • Flexible working arrangements
  • Keeping the practice culture intact
  • Making sure patients don't get disrupted

Buyers often prioritize:

  • Getting everything standardized quickly
  • Unified systems and protocols
  • Consistent financial management
  • Measurable accountability

These don't have to be at odds, but they can be if nobody talks about it upfront.

Smart deal: Both sides acknowledge these priorities early, get specific about what "autonomy" or "support" actually means, and build that into the agreement. You actually talk about what happens post-close and how decisions will be made.

Less-smart deal: Seller assumes they'll run things the same way post-close. Buyer assumes they're buying a fully integrated platform. Both walk away unhappy when reality doesn't match expectations.

Post-close continuity and practice support

Sophisticated sellers are more frequently evaluating the actual support infrastructure they'll receive post-close.

Questions sellers increasingly ask:

  • What does the onboarding process look like, and how long does it take?
  • Will the practice receive dedicated support during transitions?
  • How much disruption should we expect during integration?

Smart buyers know this matters. Groups that can demonstrate structured onboarding processes, dedicated integration teams, measured system migrations, and genuine commitment to practice continuity are winning more deals and achieving better post-close performance.

If you're evaluating a potential buyer, these questions matter. Get concrete answers. Don't settle for promises; get specific timelines and commitments.

Acquisitions versus de novo growth in a selective market

Market footprint and growth capacity

The choice between acquisitions and de novo development comes down to what your platform can actually support. Where are you growing? Can you recruit there? And do you have the capital and team to make the model work?

Acquisitions give you a running start, not a finished integration. You get an existing patient base, provider relationships, staff, and revenue. In a crowded market, those relationships can be more valuable than starting a new brand from zero. For specialty practices, there’s another advantage: referral relationships you would otherwise have to build yourself.

But you're also buying the way that practice does things. That might mean inefficient billing, fragmented RCM, and a team that isn’t interested in adjusting their current workflows. The real question you have to ask is can you improve operations without losing the people and relationships you paid for?

De novos let you build your operating model from the start. That means your technology, workflows, training, and culture. You can put the playbook in place before the first patient arrives instead of spending time untangling someone else’s processes.

The catch? You still have to fill the chairs. A de novo may make sense in an underserved or growing market, but you need a real plan to attract patients and build a schedule. A clean slate is an opportunity, not a guarantee.

Before choosing a model, it might be worthwhile to consider:

  • Is this market underserved or growing, or would we be competing for patients against established practices?
  • How important are existing patient and referral relationships to success at this location?
  • Can we recruit a new team here, or does an acquisition offer a team we can retain?
  • Do we have a repeatable launch playbook, an effective integration process, or both?

Staffing needs and capital commitments

Both models take capital and management attention. The difference is where you spend it and how long you can wait for the location to support itself.

For de novos, budget for the ramp, not just the opening. Can your balance sheet support a location running at a deficit for potentially up to 24 months?

A de novo plan needs to account for:

  • Site readiness: Zoning, permits, construction and the financial impact of opening delays.
  • Staffing: Recruiting providers and team members, then training them around shared workflows.
  • Operational readiness: Credentialing, technology setup, and revenue cycle processes before the practice reaches full capacity.
  • Patient acquisition: A marketing and scheduling plan that turns local demand into appointments.
  • Financial runway: Funding for a slower-than-expected opening or patient ramp, not just the best-case launch.

For acquisitions, budget beyond the purchase price. Existing revenue does not mean the transition takes care of itself. You need to account for billing and coding problems, the work of improving RCM, and the risk of losing providers or staff after closing. Those are things to understand before you buy, not discover once you own the practice.

An acquisition plan needs to account for:

  • Diligence: Understanding financial performance, billing practices, inherited commitments, and cultural fit before committing.
  • Integration capacity: The people and time required to migrate systems and change workflows without overwhelming the practice.
  • Retention: A realistic plan to keep providers and staff engaged after closing. Losing the existing team can leave a buyer recruiting much like a de novo operator.
  • Transition timing: Payer credentialing and transaction requirements that may affect the schedule, depending on structure and state. Confirm the specifics with counsel.

Don't stop at purchase price versus build-out cost. What will it take to get the location running the way you need it to? Can your team handle that work while keeping the rest of the group on track?

A hybrid approach may also make the most sense: acquire where established relationships and a strong team give you an advantage, and build where local demand and your launch capabilities support a de novo.

A de novo can also help you refine the playbook you bring into acquired practices. Test your workflows, learn what works, and apply those lessons.

The bottom line: Match the model to your market, your people and your capital. A growth target alone is not a reason to buy—or build.

Preparing a DSO for the next M&A cycle

Diligence-ready reporting with the Profitability Insights Suite

If you're raising capital or pursuing acquisition, you need clean, transparent reporting. Buyers and sponsors will dig deep on your finances, as they should.

They'll likely want to know:

  • Which practices are actually profitable (and which are dragging you down)
  • Your real revenue cycle performance
  • Your overhead allocation
  • Your working capital trends

If you can't answer these questions clearly with actual data, you risk slowing down diligence and losing credibility fast.

Ascend by Dentrix’s Profitability Insights Suite is built exactly for this. It connects your practice operations, financial data, and clinical metrics to give you the transparency that buyers expect. Start building this infrastructure now if you think M&A is on the horizon. You'll thank yourself when due diligence gets serious.

Integrating acquired practices with Ascend Onboarding & Data Conversion

If you're acquiring, how quickly can you get practices onto your systems and standardized workflows? The faster and cleaner you integrate, the stronger your post-close results.

Here's the reality: Extended integration creates stress for providers and team members. It creates uncertainty. It kills momentum.

Ascend’s Onboarding & Data Conversion is designed to move fast. We can get practices fully migrated and live in 25 days or less with our FastTrack implementation. That speed matters because integration velocity directly impacts post-close performance and value realization.

Summary

The DSO market in 2027 will be selective, but it's not frozen. Capital is still available, and deals are still happening, but more for platforms that have actually done the work and invested in operations, technology, sustainability, and genuine profitability.

If you've built something real, 2027 is an opportunity. If you've been chasing growth without building fundamentals, it's probably going to be a harder year.

The groups winning in 2027 aren't the ones with the most practices. They're the ones with the strongest unit economics, the best operations, and the clearest path to sustainable value creation.

Need help getting your platform diligence-ready or thinking about how to integrate faster? That's what we're here for. We've worked through hundreds of acquisitions, and we know what actually works.

Henry Schein One is committed to supporting DSO platforms through every stage of growth and M&A. From diligence-ready reporting through fast, clean integration, we've built our tools around what actually matters in M&A success.

Frequently asked questions

What do private equity sponsors look for in a DSO?

Private equity sponsors evaluate platforms across multiple dimensions, often looking for things like:

Same-source sales growth. Are practices growing revenue organically, or is growth just from acquisitions? Organic growth is often more valuable to sponsors because it's sustainable.

Operational standardization. Are back-office functions (RCM, HR, IT, scheduling) centralized and standardized, or is each practice operating independently?

Technology integration. Do you have one unified PMS, or multiple different systems? Unified platforms are worth a significant valuation premium.

Provider economics. Do compensation models actually align provider incentives with platform goals? Misaligned economics are a value killer.

Clinical outcomes. What's your treatment acceptance rate, case completion rate, and patient retention? Sponsors want to see real numbers.

Debt management. How much debt, and how expensive? Expensive debt can limit future M&A and flexibility.

Management team. Can the current team execute the growth plan? Or will the sponsor need to replace leadership?

Many sponsors are moving away from evaluating platforms purely on practice count. A group with 50 practices, 8x EBITDA, and sustainable same-source growth is often worth more than a group with 100 practices, 3x EBITDA, and no organic growth.


Are smaller DSOs still attractive acquisition targets?

Absolutely. A 30-practice group with strong unit economics and proven leadership will attract buyers. A 100-practice group with operational chaos won't. Size matters less than quality now.

What can make smaller DSOs attractive:

  • Strong geographic footprint in attractive markets
  • Proven leadership team
  • High-quality, profitable practices
  • Established brand and patient loyalty

What can make them unattractive:

  • Poor operational standardization
  • Fragmented systems and processes
  • Weak management bench strength
  • Unsustainable provider compensation models
  • High provider turnover

A well-run 30-practice DSO will normally find acquisition interest from larger platforms, consolidators, and strategic buyers. A poorly-run 30-practice DSO might struggle to find a bid.


What is a seller's window in dental M&A?

A "seller's window" is a period when valuations are favorable and buyer demand is robust. 2021 was a seller-favorable window. We saw 8-10x multiples, aggressive bidding, cheap debt.

2025-2027 is more of a buyer's market. For sellers to get fair value in today's market:

  • You need to have real profitability and growth
  • Your financial records need to be clean and operational metrics proven
  • You should expect 12-18 month sales processes
  • You need to be realistic about valuation

If a seller is waiting for a "window" to improve, they may be waiting years. Sellers with exits in mind should prepare now: clean up operations, prove profitability, and get diligence-ready.


Should a DSO standardize on one PMS after an acquisition?

Managing multiple systems creates complexity, cost, and integration headaches. Groups with unified platforms are dramatically more efficient. They get better data. They scale better. They extract more value from AI and automation investments.

Standardization doesn't mean forcing acquired practices to use unfamiliar software for 6 months and calling it done. It means:

  • Choosing one platform (Ascend by Dentrix for most large groups)
  • Building a structured migration plan
  • Providing training and support
  • Measuring adoption and outcomes

Groups that say "we'll let practices choose what they want" often find it a mistake because standardization can be a competitive advantage.

You may also like

See all blogs
See all blogs